viernes, 4 de junio de 2021

FDA Approves LUMAKRAS (Sotorasib) for the Treatment of Adult Patients with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC

label

No hay comentarios:

Publicar un comentario